12.5 C
New York
Wednesday, May 25, 2022

Lineage Cell Therapeutics (LCTX) Stock Rose 7% After-Hours. How Did That Happen?

At last check-in after-hours trading, shares of Lineage Cell Therapeutics Inc. (LCTX) were up 7.43% at $1.59. Lineage Cell Therapeutics (LCTX) stock closed the last session at $1.48, increasing 2.78% or $0.04. Shares of the company fluctuated between $1.36 and $1.49 throughout the day. The number of shares exchanged was 1.23 million, greater than the company’s 50-day daily volume of 0.68 million and higher than its Year to date volume of 0.74 million.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


In the past 12 months, Lineage Cell Therapeutics (LCTX) stock has declined -37.55%, and in the last week, the stock has moved up 4.96%. For the last six months, the stock has lost a total of -42.41%, and over the last three months, the stock has decreased by -44.78%. The stock has returned -39.59% so far this year. LCTX stock jumped after-hours before participating in a virtual conference.

Which conference has LCTX been partaking in?

Lineage Cell Therapeutics (LCTX) is a clinical-stage biotechnology company that develops new cell therapies to address unmet therapeutic needs. Ancestry’s programs rely on its robust proprietary cell-based treatment stage, as well as associated in-house development and assembly capabilities. LCTX uses its pluripotent and begetter cell starting materials to produce and construct specific, terminally separated human cells at this stage. These distinct cells are designed to either replace or maintain cells that have become worthless or absent as a result of degenerative illness or traumatic damage or to support the body in building a robust and safe response to disease.

Lineage Cell Therapeutics (LCTX) announced that Brian M. Culley, the company’s CEO, would speak at the 2022 Virtual Growth Conference, hosted by M-Vest and organized by Maxim Group LLC.

  • On March 28th, 2022, at 10 a.m. ET/7 a.m. PT, Mr. Culley will participate in an “Ophthalmology Panel” moderated by Jason McCarthy, Ph.D., Senior Managing Director, Biotechnology.
  • Culley will also provide a business overview on Monday, March 28th, 2022, which will be available to financial backers upon request.
  • Enrolled customers will have direct access to the live board and on-demand presentation through the M-Vest platform: https://m-vest.com/occasions/2022-virtual-development-gathering.
  • A recorded webcast of the corporate presentation will be available on the Lineage site’s Events and Presentations page.

What else has LCTX shared?

Lineage Cell Therapeutics (LCTX) last week declared it was growing its original cell treatment pipeline to incorporate a new investigational item applicant, a hear-able neuronal cell relocate for the treatment of hearing misfortune, with an underlying spotlight on the treatment of hear-able neuropathy range problems. To help this new restorative exertion, LCTX has petitioned for protected innovation covering the synthesis and strategies for producing hear-able neuronal ancestors.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles